Autopsy report · NCT01391611

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

“Lack of efficacy - Futility endpoint reached”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 25 participants enrolled.
• Results were posted on the registry 3 years 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Kristen Ganjoo

Sponsor type

University, hospital or other

Conditions

Gastrointestinal Stromal Tumor (GIST)

Interventions

Pazopanib

Participants

25

Sites

2

Countries

United States

Trials that died the same way

• Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection
  “Study met predefined futility criteria for efficacy endpoints.” (83% match in meaning)
• Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty
  “The primary efficacy endpoint was not met” (82% match in meaning)
• Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
  “lack of efficacy” (76% match in meaning)
• Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
  “Lack of efficacy. Stopped at first interim evaluation point” (73% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.